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Abstract. the objective of this pilot project was to investigate 
whether the breast fine needle aspiration (FNA) technique is a 
useful tool for determining the increased risk of breast cancer in 
patients with non-palpable breast lesions. FNA is a minimally 
invasive technique that isolates mammary epithelial cells from 
breast cells in the suspicious region. In this study, two FNA 
samples were collected from 12 patients. The level of HER2/
neu expression at the mRNA level (in serum) was measured in 
each patient. As gene amplification is characteristic of cancer 
cells and may assist in diagnosis and prognostic assessment, it is 
crucial that gene amplification of HER2/neu in patients with non-
palpable breast lesions is compared to breast biopsy results. In 
serum, the level of HER2/neu was determined by ELISA assay. 
Gene amplification was determined by PCR and confirmed by 
IHC employing monoclonal ERRB2 in the FNA sample. The 
results indicate that FNA has a good correlation with breast 
biopsy. FNA combined with mammographic imaging is a strong 
tool for determining favorable treatment options for patients.
Introduction
Breast cancer is believed to be the result of progressive 
molecular and morphological changes that develop in ductal 
epithelial cells. These changes have been studied extensively. 
Current detection methods can only identify in situ or invasive 
diseases. We know that the vast majority, if not all, of these 
cancers have a pre-cancerous phase. Newer methodologies 
are evolving to shift this treatment paradigm to predict which 
women are at the highest risk of developing breast cancer and 
to prevent the development of cancerous lesions.
Widespread screening with mammography and physical 
breast examination have been shown to reduce breast cancer 
mortality. However, many examinations are false-positive, 
with positive predictive values for non-palpable and palpable 
lesions ranging from 15-38% (1-3). Prior to the advent of 
percutaneous biopsy methods, many women underwent open 
surgical biopsy. With the introduction of the percutaneous 
sampling of non-palpable lesions, fine needle aspiration (FNA) 
biopsy and core-needle biopsy have been used more widely in 
the evaluation of non-palpable breast lesions (4-6).
Wrensch et al (7) analyzed nipple aspirate fluid collected 
from more than 2,700 women. This study, which had an 
average follow-up of 12.7 years, demonstrated that women 
with cellular atypia had a relative risk of developing breast 
cancer that was 4.9 times greater than that of women who did 
not have atypical cells. The 95% confidence interval for this 
finding was 1.7-13.9. 
Women with a first-degree family history of breast cancer 
in addition to atypical cells had an 18-fold increased relative 
risk; however, the extremely wide confidence interval of 
4.6-70.2, determined with a small number of subjects, casts 
some doubt on the strength of this association. The presence 
of atypia confers an increased risk for the development of 
breast cancer. Wrensch et al confirmed these findings in a 
follow-up study published in 2001 (8). Fabian et al (9), using 
ductal epithelial cells collected with random periareolar fine-
needle aspiration from 480 high-risk women, demonstrated 
similar results. This study, which had a median follow-up of 
45 months, found that high-risk women with atypical cells 
had a relative risk of developing breast cancer that was 5 times 
greater than high-risk women without atypical cells. The 95% 
confidence interval ranged from 2.0 to 12.6.
Until a cure is found, the early detection of breast cancer 
is imperative. Improved methods to detect and diagnose 
breast cancer early, when it is most curable, are required if 
a significant impact on breast cancer-related morbidity and 
mortality is to be made. Over 95% of breast cancers begin 
in the cells lining the breast ducts (10). It can take up to 
8-10 years before these cells grow into a tumor large enough 
to be detected by mammography. Two innovative technolo-
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gies to monitor for atypical ductal epithelial cells are ductal 
lavage (dL) (11) and nipple aspirate fluid (NAF) (12), which, 
in conjunction with the detection of novel biomarkers linked 
to breast cancer, are being investigated for use in the early 
detection and diagnosis of breast cancer. However, dL or 
NAF cytology alone is not sufficiently sensitive to identify 
the subgroup of women who are on a progressive pathway 
leading to breast cancer (13). 
Gene amplification is a characteristic feature of cancer cells 
that results in increased production of specific proteins required 
for the acquisition and maintenance of the malignant pheno-
type. Amplification of certain oncogenes plays an important 
role in the progression of many types of tumors (14-16). For 
example, the myCN oncogene is amplified in neuroblastomas, 
myC and myCL are amplified in small-cell lung cancer, 
and HER2/neu is amplified in breast and ovarian cancers. 
detection of such amplifications may, in some instances, assist 
in diagnosis and in prognostic assessment. Gene amplification 
also contributes to the development of resistance to cytotoxic 
drugs. V-Erb-B2 erythroblastic leukemia viral oncogene 
homolog 2 or the HER2/NEU (Her-2/neu) oncogene, which 
codes for a 185-kda transmembrane growth factor receptor, 
is amplified and/or overexpressed in 15-35% of breast carci-
nomas (17-20). The association of HER2/neu amplification and 
overexpression with rapid proliferation, low estrogen receptor 
content and high-grade ductal carcinomas suggests that this 
oncogene plays an important role in the progression of breast 
cancer. The preoperative detection of HER2/neu amplification 
in non-palpable breast lesion patients using FNA may be of 
particular relevance and could be useful clinically.
Our objective in this study was to compare the level of 
HER2/neu gene amplification in patients with non-palpable 
breast lesions with the presence or absence of atypical cells in 
their breast cells obtained by employing FNA. 
The amplification of the HER2/neu gene is more frequent 
in carcinoma in situ than in invasive types (21). detection of 
HER2/neu by a PCR-based method may aid in the diagnosis 
of non-palpable breast lesions in women with unclear or dense 
mammography images. Since this gene amplification is related 
to high proliferation, it may provide useful preoperative infor-
mation regarding certain types of intraductal carcinoma, and 
may also predict the response to chemotherapy. 
Materials and methods
Breast samples. Twelve patients were enrolled in this pilot 
project: 9 patients with a non-palpable breast lesion and 
3 healthy control women without breast cancer. FNA was used 
to obtain a breast specimen in the non-palpable breast lesion 
patients and healthy control women. A written consent form 
was signed by each patient prior to the sampling. A general 
schema of the procedures carried out in this study is shown 
in Fig. 1. 
Fine needle aspiration technique. The FNAs were performed 
by a gynecologist in a preoperative room. In this technique, 
a thin 21-G needle with a 10-ml syringe was inserted into 
the breast, and the cells were aspirated. In non-palpable 
breast lesion patients, a blind sample from suspicious breast 
tissue was isolated. The extracted cells were used to make 
two smears on slides which were stained with PAP stain and 
examined under an optical microscope. FNA is a safe and 
minor surgical procedure and less traumatic than an open 
surgical biopsy. Significant complications are usually rare 
and depend on the body site. The skin above the insertion 
area was swabbed with an antiseptic solution and draped 
with sterile surgical towels. In the normal healthy control 
women, the FNA procedure was performed in both breasts 
(two each). 
Blood serum sample. A peripheral blood sample (10 ml) was 
taken from each patient after FNA. The serum was isolated 
and maintained at -20˚C until the HER2/neu gene expression 
ELISA assay was performed for all of the patient samples.
Figure 1. General schema of the procedures employed in this study. From each patient two sample types were collected: a peripheral blood sample and a 
breast fine needle aspirate (FNA) from the non-palpable lesions. The blood sample was separated into two samples: one to isolate dNA and the other to obtain 
serum. The total dNA samples were employed to analyze HER2/neu mRNA expression by PCR, and the serum samples were utilized to quantify HER2/neu 
protein levels using ELISA assay. The FNA samples were analyzed by a cytopathologist to observe the quality of the FNA sample (number of cells) and to 
study the type of epithelial cells present in the sample. The acellular FNA samples were inadequate for analysis.
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DNA isolation from breast samples. Genomic dNA was 
isolated from the blood samples using Nexttec™ Clean 
Columns (Nexttect Inc., Leverkusen, Germany). As opposed 
to other protocols, no dNA was retained by the column 
resin. Instead, proteins, detergents and low-molecular-weight 
compounds were retained. The dNA was passed through the 
column during a short, one-step purification procedure. 
Amplification of the HER2/neu gene by PCR-based method. 
Genomic dNA (100 ng) was amplified for the HER2/neu 
gene by PCR methodology using Taq dNA polymerase 
(Promega) followed by the thermocycling program: after 
denaturalization at 95˚C for 2 min, 35 cycles of denatu-
ralization at 95˚C for 30 sec, annealing at optimal primer 
temperature for 30 sec, an extension cycle at 72˚C for 30 sec 
and a final extension at 72˚C for 10 min were performed. 
The PCR reaction was performed with a specific primer 
sequence that codifies for the HER2/neu gene. A parallel 
PCR reaction was also performed to amplify β-actin as a 
control gene amplification. 
HER2/neu ELISA assay. The HER2/neu ELISA kit is a 
sandwich-type enzyme immunoassay that utilizes two mono-
clonal antibodies directed to the extracellular domain (ECd) 
of HER2/neu. The assay quantifies either the full-length 
molecule in tumor tissue (p185) or the ECd (p105) in serum, 
plasma, cell cultures and fluids. The capture antibody was 
immobilized on the interior surface of the microplate wells. 
To perform the assay, an appropriate volume of specimen was 
incubated in the coated wells to allow binding of the antigen 
by the capture antibody. The immobilized antigen was reacted 
with the detector antiserum. The amount of detector antibody 
bound to the antigen was measured using a colored reaction 
product that was quantitated by spectrophotometry reflecting 
the amount of protein in the sample.
Results
Breast fine needle aspiration cytology. Our main objective 
in this pilot study was to determine whether breast FNA is 
feasible and accurate compared to breast biopsy in patients 
Table I. Cytopathology report from breast fine needle aspirate samples.
 
Patient Id no. Age Family Clinical Breast FNA sample Cytopathology
no.  (years) history diagnosis  report
 
  1 806200351 65 No Non-palpable Good cellularity malignant cells
    breast carcinoma with blood
  2 806200279 37 no Non-palpable Few epithelial cells Cellular atipia
    breast carcinoma
  3 807010752 72 yes Non-palpable Few epithelial cells Cellular atipia
    breast carcinoma
  4 807101541 49 yes Non-palpable Good cellularity Benign breast
    breast carcinoma  epithelial cells
  5 807280700 30 yes Non-palpable Good cellularity Benign breast
    breast carcinoma  epithelial cells
  6 807021404 64 yes Non-palpable n/p n/p
    breast carcinoma
  7 808062023 50 yes Non-palpable Acellular material Acellular material
    breast carcinoma
  8 8101510882 58 no Non-palpable Acellular material Acellular material
    breast carcinoma
  9 8101510878 62 no Non-palpable Good cellularity Benign breast
    breast carcinoma  with blood epithelial cells
10 8103102312 28 no Control patient Acellular material Acellular material
11 810290262 39 yes Control patient Acellular material Acellular material
12 811042114 60 yes Control patient Few epithelial cells Benign breast
       epithelial cells
 
The FNA cytopathologic reports and FNA quality for all patients involved in this study are included. Patient Id, age (years) and clinical 
diagnoses are also indicated. Good cellularity, >100 epithelial cells; few epithelial cells, between 20 and 50 cells; acellular material, <20 cells 
in the FNA sample. n/p, not performed.
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with non-palpable breast lesions. nine non-palpable breast 
lesion patients (30-72 years of age) and 3 healthy control 
patients (28-60 years of age) were studied. FNA was 
performed in 12 patients: 9 with non-palpable breast lesions 
and 3 healthy control women. The efficiency of FNA is 
documented in Table I. The FNA results revealed that 2/9 non-
palpable breast lesion patients had acellular material in their 
FNA samples, in 1/9 patients FNA was not performed, and in 
6/9 patients cellular material was obtained (66.6%). Among 
the 6 patients for whom cellular material was obtained, the 
cytopathology report indicated that 3/6 had benign breast 
cells (50%), 2 had cellular atipia (33.3%) and 1 had malignant 
breast cells (16.7%) in their FNAs. Of the 3 healthy control 
women, only 1 exhibited benign breast epithelial cells in the 
FNA sample and the remaining patients had acellular mate-
rial. Fig. 2A shows an image of an FNA sample from a control 
female subject, and B-F are images from the breast cytology. 
Fig. 2B is a representative image of an FNA sample with acel-
lular material, and C shows benign breast cells from a healthy 
control woman. Fig. 2d shows malignant or tumoral breast 
cells from a non-palpable breast lesion from patient no. 1, and 
E shows an FNA sample of benign breast epithelial cells from 
a non-palpable breast lesion patient. Fig. 2F is a representative 
image of an FNA sample with cellular or mild atipia.
HER2/neu protein expression in serum samples. the levels 
of HER2/neu protein expression in serum from patient nos. 
1, 2, 4, 5 and 6 with non-palpable breast lesions are shown in 
Fig. 3. One healthy control woman was included as a negative 
control, and one invasive (HER2+) breast carcinoma patient 
as positive control. The levels of HER2 protein expression in 
serum were low in all of the patients with non-palpable breast 
lesions, which were considered HER2-. The serum samples 
were analyzed from some of the available patients included 
in this study. 
HER2/neu gene expression in blood samples. HER2/neu 
gene amplification of the control dNA sample from a healthy 
control woman as a control of gene expression employing the 
housekeeping gene β-actin is shown in Fig. 4A. The molecular 
weights corresponding to HER2/neu and β-actin amplification 
bands are 198 and 550 bp, respectively. The intensity relation-
ship (R) values between HER2/neu and β-actin amplification 
bands were employed to semi-quantify the HER2/neu expres-
sion level in the remaining patients. HER2/neu and β-actin 
gene amplification in patient nos. 1-9 is shown in Fig. 4B. The 
levels of HER2/neu expression with respect to β-actin in all of 
the patients as well as in the dNA control, are represented in 
Fig. 5A. The value of R (HER2/neu/β-actin) was considered 
to be 1.0 in the dNA control. Fig. 5B shows the R values of 
all of the patients. As shown in Fig. 5B, patient nos. 1, 4, 8 and 
9 had a >1.5-fold increase in HER2/neu gene expression with 
respect to the control. However, patient nos. 2, 5 and 7 had 
a >2.0-fold lower HER2/neu gene expression with respect to 
the control. Patient nos. 3 and 6 demonstrated HER2/neu gene 
expression at the same level when compared to the control 
dna.
Discussion
mammography is generally accepted as a useful diagnostic 
clinical tool for characterizing known breast lesions so that 
appropriate and timely treatment can be administered. 
However, it remains grossly underutilized at what it does best: 
screening. Breast FNA is a minimally invasive procedure that 
allows the collection of representative breast epithelial cells 
for diagnosis and is reliable in the assessment of prognostic 
and predictive markers in breast cancer. The sensitivity of 
Figure 2. (A) Representative image of the breast fine needle aspiration samples 
from a normal patient. (B-F) microphotography of breast FNA samples. The 
FNA samples were isolated by a gynecologist. After the samples were col-
lected, the slides with the material were used immediately and maintained 
in alcohol (70%) until they were transported to the cytopathology laboratory. 
Each slide with an FNA sample was stained and analyzed under an optical 
microscope at x20 and x40. (B) Acellular material, (C) benign breast cells 
from a healthy control woman, (d) malignant or tumoral breast cells, (E) 
FNA sample with benign breast epithelial cells and (F) cellular atipia.
Figure 3. Levels of HER2/neu protein expression by ELISA assay. HER2/
neu levels measured in ng/ml in serum samples by ELISA assay employing 
automatic equipment system. Six out of 9 patients were analyzed, and negative 
and positive samples were also used as controls. 
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mammography in cancer detection needs to be high, but it is 
also important in order to achieve a high diagnostic specificity 
to avoid the morbidity associated with unnecessary surgical 
biopsy. It is in this area that we envision FNA as a useful 
tool – to determine whether or not to perform surgery on a 
lesion that is non-palpable and without a clear mammography 
image. In this study, we demonstrated that FNA has a very 
good correlation with breast biopsy. The presence of atypical 
hyperplasia in the breast FNA sample plus a suspicious 
mammographical image is a powerful tool for defining favor-
able treatment options for that patient. 
Immunohistochemistry (IHC) provides a useful method 
for defining the type of cancer a patient has and the prognosis. 
Based on this information, a course of treatment can be deter-
mined according to the factors that the cancerous cells may 
be receptive to. A patient bearing cancer with an overexpres-
sion of HER2/neu has a poor prognosis, but is a candidate for 
treatment with Herceptin. Thus, IHC yields quick results, is 
cost effective and is easy to perform. 
Further investigation is warranted to confirm whether 
FNA is a suitable method for predicting and analyzing the 
development of breast cancer. It is crucial that more samples 
from different patients are collected in order to determine 
whether there is a correlation between the level of HER2/
neu expression and breast cancer development. Follow-up 
is also recommended for a determined number of years (at 
least five) to determine whether the patient develops breast 
cancer.
These findings provide strong support to a previous 
study (8), which demonstrated that hyperplasia and atypical 
hyperplasia diagnosed in nipple aspirates of breast fluid are 
associated with an increased risk of breast cancer.
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Figure 5. HER2/neu mRNA level expression by PCR assay. The graphical images represent the quantification of the HER2/neu expression level from Fig. 4. 
The agarose gels were scanned, and each band was quantified to analyze the relative expression with respect to β-actin. (A) The level of expression in both 
HER2/neu and β-actin bands from all patients and (B) the relative expression of HER2/neu at the mRNA level with respect to β-actin.
Figure 4. HER2/neu mRNA expression by PCR analysis. (A) A HER2/neu PCR product of control dNA from a normal control woman. β-actin was also 
amplified to normalize the HER2/neu expression in each sample. (B) The HER2/neu PCR products in the 9 patients with non-palpable breast lesions. β-actin 
was used as  a control.
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